
Eli Lilly
LEI FRDRIPF3EKNDJ2CQJL29, SWIFT LLYCUS33XXX
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Profile
|
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
|
General information
-
Organization nameEli Lilly & Company
-
Organization statusOperating organization
-
AddressLilly Corporate Center Indianapolis, USA, 46285
-
Site
-
IR Site
News
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
Stocks
General information
-
Organization nameEli Lilly & Company
-
Organization statusOperating organization
-
AddressLilly Corporate Center Indianapolis, USA, 46285
-
Site
-
IR Site
Codes
-
LEIFRDRIPF3EKNDJ2CQJL29
-
SWIFTLLYCUS33XXX
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
ICB4,500 Health Care
-
CIK0000059478
-
EIN35-0470950









